Publikationen

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Sun N, Wu Y, Nanba K, Sbiera S, Kircher S, Kunzke T, Aichler M, Berezowska S, Reibetanz J, Rainey WE, Fassnacht M, Walch A, Kroiss M. (2018) High resolution tissue mass spectrometry imaging reveals a refined functional anatomy of the human adult adrenal gland. Endocrinology. epub 2018 Jan 29
• Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M. (2016) Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology. 156(11):3895-908
• Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16(4):426-35.
• Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 75(2):G1-G34
• Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B.(2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med. 370(11):1019-28 (* equal contribution)
   

Publikationen aus dem FORTiTher- Konsortium

• Vogg N, Kurlbaum M, Deutschbein T, Gräsl B, Fassnacht M, Kroiss M. Method-specific cortisol and dexamethasone thresholds increase clinical specificity of the dexamethasone suppression test for Cushing’s syndrome. Clinical Chemistry 2021. In press.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Weide B, Schäfer T, Martens A, Kuzkina A, Uder L, Noor S, Garbe C, Harter PN, Mittelbronn M, Wischhusen J. High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients. J Invest Dermatol. pii: S0022-202X(16)32125-X. doi: 10.1016/j.jid.2016.07.016, 2016.
• Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6(38):40836-49. doi: 10.18632/oncotarget.5696, 2015. IF: 6,627
• Siegl C, Prustyl BK, Karunakaran K, Wischhusen J, Rudel T. Tumor suppressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection. Cell Rep. 9(3):918-29, 2014. partial IF: 8.358
• Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick R, Bauer A, Wischhusen J, Beier M, Kohlhaas J, Katus HA, Hoheisel J, Franke A, Meder B, Meese E. miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med. 12:224, 2014. doi: 10.1186/s12916-014-0224-0. IF: 7.249.
• Diessner J, Bruttel V, Stein RG, Horn E, Häusler SF, Dietl J, Hönig A, Wischhusen J. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis. 5:e1149m 2014. doi: 10.1038/cddis.2014.115. IF: 5,965.

Publikationen aus dem FORTiTher- Konsortium

• Wischhusen J, Melero I, Fridman WH. (2020) GDF-15: From Biomarker to Novel Targetable Immune Checkpoint. Frontiers in Immunology
• Kühnemundt J, Leifeld H, Scherg F, Schmitt M, Nelke LC, Schmitt T, Baur F, Göttlich C, Fuchs M, Kunz M, Peindl M, Brähler C, Kronenthaler C, Wischhusen J, Prelog M, Walles H, Dandekar T, Dandekar G, Nietzer SL. (2020) Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing. ALTEX. 38(2):289-306.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Docheva D, Padula D, Schieker M, Clausen-Schaumann H. Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. BBRC 2010. 402(2):361-6.
• Saller MM, Prall WC, Docheva D, Schönitzer V, Popov T, Anz D, Clausen-Schaumann H, Mutschler W, Volkmer E, Schieker M, Polzer H. Increased stemness and migration of human mesenchymal stem cells in hypoxia is associated with altered integrin expression. BBRC 2012. 423(2):379-85.
• Sariisik E, Docheva D, Padula D, Popov T, Opfer J, Schieker M, Clausen-Schaumann H, Benoit M. Probing the interaction forces of prostate cancer cells with collagen I and bone marrow derived stem cells on the single cell level. PLoS One. 2013. 8(3):e57706.
• Sariisik E, Popov T, Müller JP, Docheva D, Clausen-Schaumann H, Benoit M. Decoding Cytoskeleton-Anchored and Non-Anchored Receptors from Single-Cell Adhesion Force Data. Biophys J. 2015. 109(7):1330-3.
• Prall WC, Saller MM, Scheumaier A, Tucholski T, Taha S, Böcker W, Polzer H. Proliferative and osteogenic differentiation capacity of mesenchymal stromal cells: Influence of harvesting site and donor age. Injury. 2018. 49(8):1504-1512.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, Naimer V, Polzer B, Treitschke S, Werno C, Markiewicz A, Weidele K, Czyz Z, Hohenleutner U, Hafner C, Haferkamp S, Berneburg M, Rummele P, Ulmer A, Klein C.A. (2018). Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun 9, 595.
• Hosseini H, Obradovic MM, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, Patwary N, Haunschild G, Guzvic M, Reimelt C, Grauvogl M, Eichner N, Weber F, Hartkopf AD, Taran FA, Brucker SY, Fehm T, Rack B, Buchholz S, Spang R, Meister G, Aguirre-Ghiso JA, Klein CA. (2016). Early dissemination seeds metastasis in breast cancer. Nature 540, 552-558.
• Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, Gianni S, Calanca A, Signorini G, Bolognesi C, Hartmann A, Fasching PA, Sandri MT, Rack B, Fehm T, Giorgini G, Manaresi N, Klein CA. (2014). Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO molecular medicine 6, 1371-1386.
• Czyz ZT, Hoffmann M, Schlimok G, Polzer B, Klein CA. (2014). Reliable Single Cell Array CGH for Clinical Samples. PloS one 9, e85907.
• Klein CA. (2013). Selection and adaptation during metastatic cancer progression. Nature 501, 365-372

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Treiber T, Treiber N, Plessmann U, Harlander S, Daiß JL, Eichner N, Lehmann G, Schall K, Urlaub H, Meister G. (2017) A compendium of RNA-binding proteins that regulate microRNA biogenesis. Molecular Cell, 66(2):270-284.
• Hosseini H, Obradović MM, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, Patwary N, Haunschild G, Gužvić M, Reimelt C, Grauvogl M, Eichner N, Weber F, Hartkopf AD, Taran FA, Brucker SY, Fehm T, Rack B, Buchholz S, Spang R, Meister G, Aguirre-Ghiso JA, Klein CA. (2016) Early dissemination seeds metastasis in breast cancer. Nature, doi: 10.1038/nature20785.
• Hasler D, Lehmann G, Murakawa Y, Klironomos F, Jakob L, Graesser FA, Rajewsky N, Landthaler M, Meister G. (2016) The Lupus Autoantigen La Prevents Mis-channeling of tRNA Fragments into the Human MicroRNA Pathway. Molecular Cell, 7;63(1):110-24.
• Loedige I, Jakob L, Treiber T, Ray D, Stotz M, Treiber N, Hennig J, Cook KB, Morris Q, Hughes TR, Engelmann JC, Krahn MP, Meister G. (2015) The Crystal Structure of the NHL Domain in Complex with RNA Reveals the Molecular Basis of Drosophila Brain-Tumor-Mediated Gene Regulation. Cell Rep. 13(6):1206-20.
• Loedige I, Stotz M, Qamar S, Kramer K, Hennig J, Schubert T, Löffler P, Längst G, Merkl R, Urlaub H, Meister G. (2014) The NHL domain of BRAT is an RNA-binding domain that directly contacts the hunchback mRNA for regulation. Genes Dev., 28(7): 749-764.

Publikationen aus dem FORTiTher- Konsortium

• Ho-Xuan H, Lehmann G, Glazar P, Gypas F, Eichner N, Heizler K, Schlitt HJ, Zavolan M, Rajewsky N, Meister G, Hackl C.  (2020) Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers (Basel). 13(1):49.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Ebert R, Meissner-Weigl J, Zeck S, Määttä J, Auriola S, Coimbra de Sousa S, Mentrup B, Graser S, Rachner TD, Hofbauer LC, Jakob F. (2014) Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Mol Cancer, 13(1):265.
• Ebert R, Benisch P, Krug M, Zeck S, Meißner-Weigl J, Rauner M, Hofbauer L, Jakob F. (2015) Acute phase serum amyloid A induces proinflammatory cytokines and mineralization via toll-like receptor 4 in mesenchymal stem cells. Stem Cell Research, 15:231-239.
• Dotterweich J, Tower RJ, Brandl A, Müller M, Hofbauer L, Beilhack A, Ebert R, Glüer C, Tiwari S, Schütze N, Jakob F. (2016) The KISS1 Receptor as an in vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One, 11(5): e0155087.
• Dotterweich J, Schlegelmilch K, Keller A, Tower RJ, Klein-Hitpass L, Linden C, Geyer B, Ebert R, Jakob F, Schütze N. (2016) Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells – implications for myeloma bone disease. Bone, 93: 155-166.
• Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Rudelius M, Dotterweich J, Ebert R, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. (2018) Jam-A as a prognostic factor and new therapeutic target in Multiple Myeloma, Leukemia, 32(3):736-743.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Wittmann K, Dietl S, Ludwig N, Berberich O, Hoefner C, Storck K, Blunk T, Bauer-Kreisel P. Engineering vascularized adipose tissue using the stromal-vascular fraction and fibrin hydrogels, Tissue Eng. A 21, 1343-1353 (2015).
• Wittmann K, Storck K, Muhr C, Mayer H, Regn S, Staudenmaier R, Wiese H, Maier G, Bauer-Kreisel P, Blunk T. Development of volume-stable adipose tissue constructs using polycaprolactone-based polyurethane scaffolds and fibrin hydrogels, J. Tissue Eng. Regen. Med. 10, E409-E418 (2016).
• Wiesner M, Berberich O, Hoefner C, Blunk T, Bauer-Kreisel P. Gap junctional intercellular communication in adipose-derived stromal/stem cells is cell density-dependent and positively impacts adipogenic differentiation, J. Cell. Physiol. 233, 3315-3329 (2018).
• Hrynevich A, Şen Elçi B, Haigh JN, McMaster R, Youssef A, Blum C, Blunk T, Hochleitner G, Groll J, Dalton PD. Dimension-based design of melt electrowritten scaffolds, Small 14, e1800232 (2018).
• Böck T, Schill V, Krähnke M, Steinert AF, Tessmar J, Blunk T, Groll J. TGF-1-modified hyaluronic acid / poly(glycidol) hydrogels for chondrogenic differentiation of human mesenchymal stromal cells, Macromol. Biosci. (2018). doi: 10.1002/mabi.201700390. 

Publikationen aus dem FORTiTher- Konsortium

• Hoefner C., Muhr C., Horder H., Wiesner M., Lukaszyk D., Radeloff K., Winnefeld M., Becker M., Blunk T., Bauer-Kreisel P. (2020). Human Adipose-Derived Mesenchymal Stromal/Stem Cell Spheroids Possess High Adipogenic Capacity and Acquire an Adipose Tissue-like Extracellular Matrix Pattern. Tissue Eng Part A 26, 915-926. 

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desanti V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. (2018). JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia 32(3):736-743.
• Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, Ott G, Rosenwald A. (2017). Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow micro-environment. Haematologica 103(1):116-125.
• Dotterweich J, Tower RJ, Brandl A, Müller M, Hofbauer LC, Beilhack A, Ebert R, Glüer CC, Tiwari S, Schütze N, Jakob F. (2016). The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One. 11(5):e0155087.
• Brede C, Friedrich M, Jordán-Garrote AL, Riedel SS, Bäuerlein CA, Heinze K, Bopp T, Schulz S, Mottok A, Kiesel C, Mattenheimer K, Ritz M, von Krosigk V, Rosenwald A, Einsele H, Negrin RS, Harms GS, Beilhack A. (2012) Mapping immune processes in intact tissues at cellular resolution. J Clin Invest 122 (12): 4439-4446.
• Riedel SS, Mottok A, Brede C, Bäuerlein CA, Jordán Garrote AL, Ritz M, Mattenheimer K, Rosenwald A, Einsele, H, Bogen B, Beilhack A. (2012). Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS ONE 7: e52398.

Publikationen aus dem FORTiTher- Konsortium

• Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm KM, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A. (2020). Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica, in press
• Rummler M, Ziouti F, Bouchard AL, Brandl A, Duda N, Bogen B, Beilhack A, Lynch ME, Jundt F*, Willie BM*. (2020). Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease. Acta Biomaterialia 119:247-258.
• Da Vià MC, Solimando AG, Garitano‐Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM. (2019). CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. The Oncologist 24:1-7.
• Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A*, Einsele H*. (2019). High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 8(7): 997.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, Pietschmann E, Habringer S, Gerngross C, Franke K, et al. (2015). In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. Embo Mol Med 7, 477-487.
• Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hanscheid H, Luckerath K, Schreder M, Bluemel C, Knott M, et al. (2016). First-in-Human Experience of CXCR4-Directed Endoradiotherapy with Lu-177- and Y-90-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med 57, 248-251.
• Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerath K, Schottelius M, Wester HJ and Lapa C. (2017). Chemokine Receptor-directed Imaging and Therapy. Methods.
• Lapa C, Lückerath K, Kircher S, Hänscheid H, Grigoleit GU, Rosenwald A, Stolzenburg A, Kropf S, Einsele H, Wester HJ. (2018). Potential influence of concomitant chemotherapy on CXCR 4 expression in receptor directed endoradiotherapy. British journal of haematology.
• Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid JS, Grigoleit GU, Hofmann S, Beer AJ, Bunjes D. (2018). Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol I, 1-11.

Publikationen aus dem FORTiTher- Konsortium

• Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. (2021) CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel) 29;11(4):605.
• Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, Rasche L, Buck AK, Wester HJ, Rosenwald A, Einsele H, Topp MS, Lapa C, Kircher M. (2021)  Improved primary staging of marginal zone lymphoma by addition of CXCR4-directed PET/CT. J Nucl Med. 12.
• Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J, Habringer S, Lapa C, Pukrop T, Hellwig D, Wiestler B, Buck AK, Deckert M, Wester HJ, Bassermann F, Schwaiger M, Weber W, Menze B, Keller U. (2020) CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. J Nucl Med. 61(12):1765-1771.
• Kircher M, Tran-Gia J, Kemmer L, Zhang X, Schirbel A, Werner RA, Buck AK, Wester HJ, Hacker M, Lapa C, Li X. (2020) Imaging Inflammation in Atherosclerosis with CXCR4-Directed 68Ga-Pentixafor PET/CT: Correlation with 18F-FDG PET/CT. J Nucl Med. 61(5):751-756.
• Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, Buck AK, Pomper MG, Rowe SP, Lapa C.  (2019) CXCR4-Directed Imaging in Solid Tumors. Front Oncol. 9:770.
• Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C, Schirbel A, Rowe SP, Pomper MG, Buck AK, Wester HJ, Ernestus RI, Lapa C. (2019) [68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. Front Oncol. 9:503.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Schweinlin S, Wilhelm S, Schwedhelm I, Hansmann J, Ritscher R, Jurowich C, Walles H, Metzger M.. Development of an advanced primary human in vitro model of the small intestine” Tissue Engineering Part C: Methods 2016 Sep;22(9):873-83.
• Appelt-Menzel A, Neuhaus W, Cubukova A, Wilhelm A, Günther K, Edenhofer F, Piontek J, Krause G, Stüber T, Walles H, Metzger M. Establishment of a human blood-brain barrier co-culture model mimicking the neurovascular unit using induced pluripotent and multipotent stem cells. Stem Cell Reports 2017 Apr 11;8(4):894-906.
• Kress S, Baur J, Otto C, Burkard N, Braspenning J, Walles H, Nickel J, Metzger M. Evaluation of a Miniaturized Biologically Vascularized Scaffold in vitro and in vivo. Sci Rep. 2018 Mar 16;8(1):4719.
• Nietzer S, Baur F, Sieber S, Hansmann J, Schwarz T, Stoffer C, Häfner H, Gasser M, Waaga-Gasser AM, Walles H, Dandekar G. Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold. Tissue Eng Part C Methods. 2016 Jul;22(7):621-35.
• Göttlich C, Kunz M, Zapp C, Nietzer SL, Walles H, Dandekar T, Dandekar G. A combined tissue engineered / in silico signature tool for patient stratification in lung cancer. Mol Oncol. 2018 May 24. doi: 10.1002/1878-0261.12323.

Publikationen aus dem FORTiTher- Konsortium

• Kühnemundt J, Leifeld H, Scherg F, Schmitt M, Nelke LC, Schmitt T, Baur F, Göttlich C, Fuchs M, Kunz M, Peindl M, Brähler C, Kronenthaler C, Wischhusen J, Prelog M, Walles H, Dandekar T, Dandekar G, Nietzer SL. (2020) Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing. ALTEX. 38(2):289-306.

Ausgewählte Publikationen des FORTiTher-Konsortiums vor Projektbeginn

• Göttlich C, Kunz M, Zapp C, Nietzer SL, Walles H, Dandekar T, Dandekar G. A combined tissue-engineered/in silico signature tool patient stratification in lung cancer. Mol Oncol. 2018 Aug;12(8):1264-1285. doi: 10.1002/1878-0261.12323. Epub 2018 Jun 22.
• Göttlich C, Müller LC, Kunz M, Schmitt F, Walles H, Walles T, Dandekar T, Dandekar G, Nietzer SL. A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds. J Vis Exp. 2016 Apr 6;(110):e53885.
• Karl S, Dandekar T. Jimena: efficient computing and system state identification for genetic regulatory networks. BMC Bioinformatics. 2013 Oct 11;14:306.
• Kunz M, Göttlich C, Walles T, Nietzer S, Dandekar G, Dandekar T. MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumour Biol. 2017 Jul;39(7):1010428317706430.
• Stratmann AT, Fecher D, Wangorsch G, Göttlich C, Walles T, Walles H, Dandekar T, Dandekar G, Nietzer SL. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol Oncol. 2014 Mar;8(2):351-65.

Publikationen aus dem FORTiTher- Konsortium

• Cerezo-Echevarria A, J. M. Grassinger, C Beitzinger, R Klopfleisch, H Aupperle-Lellbach (2021) Evaluating the Histologic Grade of Digital Squamous Cell Carcinomas in Dogs with Dark and Light Haircoat—A Comparative Study of the Invasive Front and Tumor Cell Budding Systems. Vet. Sci, 8, 3.
• Kühnemundt J, Leifeld H, Scherg F, Schmitt M, Nelke LC, Schmitt T, Baur F, Göttlich C, Fuchs M, Kunz M, Peindl M, Brähler C, Kronenthaler C, Wischhusen J, Prelog M, Walles H, Dandekar T, Dandekar G, Nietzer SL. (2020) Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing. ALTEX. 38(2):289-306.